A newly developed iron-based nanomaterial shows promise in selectively destroying cancer cells although sparing healthy tissue, according to a study published in Advanced Functional Materials. Researchers at Oregon State University reported complete elimination of breast cancer in a mouse model, offering a potential pathway toward more targeted cancer therapies.
The research, which builds on the principles of chemodynamic therapy (CDT), leverages unique chemical characteristics of tumors to induce cell death. Cancer cells differ from healthy cells by exhibiting a more acidic environment and higher concentrations of hydrogen peroxide – a common disinfectant that naturally accumulates within tumors.
Tumor Cells Have a Different Chemical Environment
The new nanomaterial, described as a metal-organic framework with iron embedded in a porphyrin structure, is designed to exploit this difference. Its structure resembles tiny needles, creating a large surface area for chemical reactions. This targeted approach is significant because traditional cancer treatments often harm healthy cells alongside cancerous ones, leading to debilitating side effects.
Two Reactions Simultaneously Target Cancer Cells
Once inside a cancer cell, the material triggers two simultaneous chemical processes:
- The creation of hydroxyl radicals.
- The formation of singlet oxygen.
Both are reactive oxygen species – highly reactive molecules that strip electrons from essential cellular components like lipids, proteins, and even DNA. This causes significant oxidative stress, ultimately leading to cancer cell death. Because healthy cells contain far less hydrogen peroxide, these reactions occur to a much lesser extent in non-cancerous tissue, contributing to the observed selectivity.
Previous Approaches Often Fell Short
The research team, led by Oleh Taratula, notes that existing CDT methods typically generate only one type of reactive oxygen species. “Existing CDT agents are limited. They either produce hydroxyl radicals or singlet oxygen, but not both,” Taratula explained. They also often lacked sufficient catalytic activity, resulting in only partial tumor reduction in preclinical studies. This new material, however, combines both mechanisms with increased efficiency.
In laboratory tests, the iron nanomaterial demonstrated a strong effect against multiple cancer cell lines while leaving non-malignant tissue largely unharmed.
Complete Breast Cancer Regression in Mouse Model
In animal studies, mice with human breast cancer cells received the nanomaterial intravenously. “When we administered our nanoagent to mice with human breast cancer cells, it efficiently accumulated in the tumor and eliminated the cancer completely, without side effects,” Taratula said. “We observed complete tumor regression and long-term prevention of recurrence, without systemic toxicity.”
So the tumors completely disappeared and did not return during the observation period. Researchers found no evidence of organ damage or other systemic side effects.
Human Therapies Still Years Away
Despite these promising results, the data are currently preclinical. Further research is needed before the treatment can be tested in humans. The team plans to investigate the material’s effectiveness against other cancer types, including aggressive pancreatic cancer, before initiating clinical trials. It remains to be seen whether the findings from the mouse model will translate to humans.
The perform was funded in part by the National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
In Brief:
- The newly developed iron nanomaterial targets cancer cells by triggering two aggressive oxygen reactions within tumors while largely sparing healthy tissue.
- In mice with human breast cancer cells, treatment led to complete tumor regression without observable side effects or recurrence.
- Further research is needed in different cancer types before human applications can be considered, but the approach offers potential for more precise and potentially less toxic therapies.
Related: A large U.S. Analysis of over 26,000 adults found that higher creatine intake was associated with a lower risk of cancer. Learn more about why age remains the primary risk factor and what this means for diet in our article.
Image: © Unsplash
